Abstract
Current standard adjuvant therapies for premenopausal women with early breast cancer include ovarian ablation by surgery or irradiation, chemotherapy and tamoxifen. The value of ovarian ablation in prolonging the survival of premenopausal patients with early breast cancer was clearly established by the analyses performed by the Early Breast Cancer Trialists’ Collaborative Group in 1996. More recently, the value of ovarian suppression using the luteinizing hormone releasing hormone analogue goserelin as adjuvant therapy in pre-/perimenopausal women with early breast cancer has been confirmed in a series of studies involving over 8000 patients. The results from these studies provide evidence that goserelin, alone or in combination with tamoxifen, is at least as effective as cytotoxic chemotherapy in patients with hormone receptor-positive tumours and is effective when used after adjuvant chemotherapy. The use of goserelin in the management of early breast cancer presents an option which can avoid the side-effects experienced with cytotoxic chemotherapy and may offer unique benefits to premenopausal patients. The consolidation of these emerging results should help in defining the optimal role for goserelin in pre-/perimenopausal patients with early breast cancer. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
26 November 2002
Correction to: British Journal of Cancer 2001; (Suppl 2): 1–5 An error has been noted within Figure 1. The chemotherapy regimen shown in the ECOG/SWOG/CALGB INT-0101 study is incorrect and should be six cycles of CAF (cyclophosphamide/adriamycin/5-fluorouracil) and not six cycles of CMF (cyclophosphamide/methotrexate/5-fluorouracil), as presented.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Jonat, W. Goserelin (Zoladex ™) – its role in early breast cancer in pre- and perimenopausal women. Br J Cancer 85 (Suppl 2), 1–5 (2001). https://doi.org/10.1054/bjoc.2001.1981
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1981